| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Valor IV Pharma Holdings, LLC | 11.7% | $187M | 6.65M | Antonio J. Gracias | Dec 31, 2024 | |||
| Marshman Fund Trust II | 10.6% | $170M | 6.05M | Marshman Fund Trust II | Dec 31, 2024 | |||
| BlackRock, Inc. | 10.1% | -17.5% | $162M | -$33.7M | 5.77M | -17.2% | BlackRock, Inc. | Mar 31, 2025 |
| VANGUARD GROUP INC | 8.3% | $133M | 4.73M | The Vanguard Group | Dec 31, 2024 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 561K | $15.5M | -$870K | $27.56 | 18 |
| 2025 Q2 | 51.2M | $1.62B | +$22.9M | $31.60 | 275 |
| 2025 Q1 | 50.1M | $1.66B | -$101M | $33.19 | 266 |
| 2024 Q4 | 52.7M | $1.81B | +$76.2M | $34.41 | 244 |
| 2024 Q3 | 49.7M | $1.99B | -$3.86M | $40.00 | 231 |
| 2024 Q2 | 50.2M | $1.51B | +$39.7M | $30.17 | 218 |
| 2024 Q1 | 48.8M | $1.64B | +$42.7M | $33.58 | 207 |
| 2023 Q4 | 38.2K | $1.25M | +$137K | $32.82 | 2 |
| 2023 Q3 | 49.3M | $1.62B | -$87.1M | $32.77 | 200 |
| 2023 Q2 | 51.7M | $1.82B | +$16.4M | $35.19 | 204 |
| 2023 Q1 | 51.2M | $1.67B | -$29.5M | $32.65 | 211 |
| 2022 Q4 | 51M | $2.81B | +$33.8M | $55.10 | 235 |
| 2022 Q3 | 50.4M | $2.24B | +$101M | $44.29 | 190 |
| 2022 Q2 | 47.8M | $2.32B | +$88.9M | $48.77 | 170 |
| 2022 Q1 | 45.8M | $2.23B | +$78.3M | $48.65 | 165 |
| 2021 Q4 | 44.3M | $1.89B | +$101M | $42.64 | 136 |
| 2021 Q3 | 30.9M | $1.18B | +$115M | $38.33 | 96 |
| 2021 Q2 | 27.9M | $786M | -$9.32M | $28.23 | 78 |
| 2021 Q1 | 27.5M | $908M | -$18.5M | $33.04 | 56 |
| 2020 Q4 | 28M | $998M | -$18.7M | $36.15 | 59 |
| 2020 Q3 | 28.5M | $941M | +$941M | $33.90 | 44 |